Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Talaporfin sodium (LS11) with Litx System in high-grade glioma
NCT00409214Phase 2Completed
- Sponsor
- Light Science Oncology
- Start
- Nov 2006
- Primary completion
- Feb 2008
- Modality
- Light/Condition-Responsive Prodrugs
- Countries
- 1
01
Overview
Phase 2, open-label trial of talaporfin sodium in glioblastoma (GBM) and anaplastic astrocytoma (AA) (2 arms), sponsored by Light Science Oncology. Primary endpoints: Safety of the Litx therapy and Confirmation of the zone of tumor destruction. Started Nov 2006; status: completed.
02
Drugs
talaporfin sodium
03
Conditions
glioblastoma (GBM)anaplastic astrocytoma (AA)
Beyond the preview
Go deeper on NCT00409214.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00409214.